国家医保目录与其他药品目录收录血液制品的差异分析

Analysis on the differences of blood products between national medical insurance drug catalogue and drug catalouges

目的以血液制品为例,分析中国(含大陆及台湾地区)、澳大利亚、英国医保目录及世界卫生组织基本药物目录的药品收录情况,为我国血液制品医保目录的遴选及管理提供参考。方法采用描述性分析方法对比我国《国家基本医疗保险、工伤保险和生育保险药品目录》(以下简称国家医保目录)、中国台湾地区《全民健康保险用药品项表》(以下简称我国台湾地区健保目录)、澳大利亚《国家血液协议》(NBA)、《英国国家处方集》(BNF)及《世界卫生组织基本药物标准清单》(EML)5个目录的特点,并对目录中血液制品品种的收录情况进行统计分析。结果5个目录共收录了32种血液制品,其中我国国家医保目录收录血液制品16种,我国台湾地区健保目录收录18种,BNF、NBA、EML分别收录19种、22种和9种。国家医保目录独有的品种有3种,分别为免疫球蛋白类抗人T细胞兔免疫球蛋白、抗人T细胞猪免疫球蛋白及凝血因子类凝血酶。其他目录有收录而国家医保目录未收录的品种有16种,包括8种免疫球蛋白类、5种凝血因子类和3种微量蛋白类血液制品。结论我国国家医保目录收录的血液制品用药种数与其他4个目录相差不大,医保保障力度也比较大,但未见微量蛋白类药品的收录,通过比较分析可为我国医保目录的动态调整提供参考。

Objective Taking blood products as an example,this paper analyzed the drug loading situation in the drug reimbursement lists of china(the mainland and Taiwan),Australia,the United Kingdom,and the essential drug list of the World Health Organization(WHO),in order to provide reference for the selection and management of medical insurance catalogue of blood products in China.Methods Descriptive analysis method was used to compare the characteristic of national medical insurance catalogue,Chinese Taiwan health insurance catalogue,national blood agreement(NBA),British national formulary(BNF),and WHO model list of essential medicines(EML).Blood products varieties included in the drug reimbursement lists were compared and statistically analyzed.Results A total of 32 kinds of blood products were included in the five catalogues.Among them,16 kinds of blood products were included in the national medical insurance catalogue,18 kinds of blood products were included in Chinese Taiwan health insurance catalogue,and 19 kinds,22 kinds and 9 kinds of blood products were included in BNF,NBA,EML respectively.There are 3 kinds of unique varieties only in national medical insurance catalog,includes immunoglobulin,anti human T cell rabbit immunoglobulin,anti human T cell pig immunoglobulin and coagulation factor thrombin.There are 16 kinds of varieties are included in other catalogs but not included in national medical insurance catalog,they are 8 kinds of immunoglobulins,5 kinds of coagulation factors and 3 kinds of micro protein blood products.Conclusion The number of blood products used in China's Mainland is similar to those of the other four catalogues,and the medical insurance security is relatively strong,but there is no trace protein drugs included.This can provide reference for dynamic adjustment of medical insurance catalogue via comparing and analyzing.